Recruiting Interstitial Cystitis Studies in Clayton
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bome...
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients wit...
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
The Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leu...
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
This trial will compare tisagenlecleucel to standard of care in adult participants with relapsed or refractory (r/r) follicular lymphoma....
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin". It is a chronic (long-lasting) disease that causes swel...
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
This study will enroll participants with myelodysplastic syndromes (MDS) with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have not received treatment with a hypomethylating agent previ...
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go...
About Interstitial Cystitis Clinical Trials in Clayton
Interstitial cystitis/bladder pain syndrome is a chronic condition causing bladder pressure, bladder pain, and sometimes pelvic pain. It primarily affects women and can significantly impact quality of life. Treatment includes dietary changes, bladder instillations, oral medications, and neuromodulation.
There are currently 7 interstitial cystitis clinical trials recruiting participants in Clayton, VICTORIA. These studies are seeking a combined 1,303 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Vivace Therapeutics, Inc, Amgen and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Interstitial Cystitis Clinical Trials in Clayton — FAQ
Are there interstitial cystitis clinical trials in Clayton?
Yes, there are 7 interstitial cystitis clinical trials currently recruiting in Clayton, VICTORIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Clayton?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Clayton research site will contact you about next steps.
Are clinical trials in Clayton free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Clayton studies also compensate for your time and travel.
What interstitial cystitis treatments are being tested?
The 7 active trials in Clayton are testing new therapies including novel drugs, biologics, and treatment approaches for interstitial cystitis.
Data updated March 2, 2026 from ClinicalTrials.gov